|Year : 2015 | Volume
| Issue : 1 | Page : 44-47
Tuberculosis drug resistance isolates from pulmonary tuberculosis patients, Kassala State, Sudan
Fatima A Khalid1, Zuhal A Hamid2, MM Mukhtar3
1 Tuberculosis Research Centre, University of Kassala, Kassala, Sudan
2 National Institute of Cancer, University of Gezira, Sudan
3 Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
|Date of Web Publication||21-Feb-2017|
Fatima A Khalid
Tuberculosis Research Centre, University of Kassala
Source of Support: None, Conflict of Interest: None
Background: This study was conducted in Kassala Teaching Hospital, Kassala State, Sudan (January 2006–June 2008) to determine the rate of Mycobacterium drug resistance to anti-tuberculous treatment and to explore the genotype of Mycobacterium tuberculosis resistant isolates using rpoB gene.
Methods: 53 isolates of Mycobacterium isolated from pulmonary tuberculosis (PTB) patients from Kassala State were subjected to drug susceptibility testing (DST) to anti-tuberculous drugs; 10 M. tuberculosis complex (MTBC) resistant isolates were subjected to polymerase chain reaction (PCR), and commercially the amplified DNA was sequenced.
Results: DST detected resistance in 23/53 (43.39%) isolates, among which rifampicin had a high number of resistant isolates (13/23), followed by streptomycin (11/23), and multi-drug resistance was detected in 5 isolates.
DNA sequence analysis of 10 MTBC-resistant isolates detected variations within and outside the rifampicin resistant determining region (RRDR). Variation within RRDR was detected at positions 512 (AGC/ATC, Ser/Ile), and 528 (CGC/CTC, Arg/Leu). Outside the RRDR region variations were detected at positions 498 (GTG/GGG, Val/gly), 488 (ACA/ACC, Thr/Thr), which is a silent mutation. Insertions were observed at positions 484, 496 (GTG/GTGA, CGG/CAGG, respectively). Deletion was observed at position 487 (ATC/_TC).
Discussion and conclusion:
This study revealed that high resistance to rifampicin was associated with various point mutations in and out of the RRDR of the rpoB gene. Molecular methods are needed for early detection of TB disease and drug resistance.
Keywords: Mycobacterium tuberculosis, Drug resistance, Sudan
|How to cite this article:|
Khalid FA, Hamid ZA, Mukhtar M M. Tuberculosis drug resistance isolates from pulmonary tuberculosis patients, Kassala State, Sudan. Int J Mycobacteriol 2015;4:44-7
|How to cite this URL:|
Khalid FA, Hamid ZA, Mukhtar M M. Tuberculosis drug resistance isolates from pulmonary tuberculosis patients, Kassala State, Sudan. Int J Mycobacteriol [serial online] 2015 [cited 2021 Oct 22];4:44-7. Available from: https://www.ijmyco.org/text.asp?2015/4/1/44/200588
| Introduction|| |
Tuberculosis (TB) is a curable disease, though it still remains a major public health problem worldwide, especially in developing countries. Globally, it ranks as the second leading cause of death from an infectious disease. In 2012, the estimated new cases were 9.0 million and 1.5 million TB deaths . The situation has become alarming due to dual infection with HIV and the development of drug resistance. The emergence of resistance to drugs used for TB treatment, and particularly multidrug-resistant TB (MDR-TB), has become a significant public health problem in a number of countries and an obstacle to effective global TB control . Globally, 3.6% of new TB cases and 20.2% of previously treated cases are estimated to have MDR-TB . Both Rifampin (RIF) and Isoniazid (INH) resistance are reliable markers of MDR-TB . Resistance to RIF is caused by mutations in the β subunit of RNA polymerase, a target of RIF, which is encoded by the rpoB gene. More than 95% of the resistant strains harbor mutations within an 81-bp hot-spot region (codons 507–533) of rpoB, named RIF resistant determining region (RRDR) . In contrast, INH resistance is due to a mutation at one of two main sites, in either katG or inhA genes .
High incidence ranks Sudan among the high prevalence countries for TB in the Eastern Mediterranean region and accounts for 14.6% of the total TB burden . No clear data on MDR-TB was reported in Sudan. A few studies have reported the detection of drug resistance in some States . This study was initiated to determine the rate of Mycobacterium drug resistance to anti-tuberculous treatment and to explore the genotype of MTB-resistant isolates using rpoB gene.
| Methods|| |
Study design and sample collection
This is a descriptive cross-sectional study. It was conducted at the Chest Department, Kassala Teaching Hospital, Kassala State, Sudan during the period from 2007 to 2009. 113 of the pulmonary TB cases that were subjected to treatment based on the laboratory diagnosis and/or clinical symptoms and X-ray findings were enrolled in the present study. Each patient was requested to give an adequate sputum sample in a specific container for culture and DST.
Culture and DST
200 μL from each of the digested and decontaminated sputum samples was inoculated in Lowenstein Jensen (LJ) medium. A subculture was prepared for the successful growth samples followed by DST, which was done for 53 clinical isolates of Mycobacterium using the proportion method described by Sethi et al. . Briefly, the LJ medium with each drug incorporated in various concentrations (0.2μ/mL for INH, 40μ/mL for RIF, 4μ/mL for streptomycin [SM] and 2.0μ/mL for Ethambutol [ETH]) and a plain medium for control were prepared. The bacterial serial dilution suspensions (10−2 and 10−4) were inoculated in the prepared media, and then incubated at 37 °C. The readings of the incubated samples were taken after 28 days, and the second one was taken after 42 days. The resistance was calculated as the ratio of the number of colonies on the drug-containing medium and those of the control media. The isolate was considered as resistant if the ratio was greater or equal to 1% .
DNA extraction, amplification and sequencing
DNA was extracted by boiling method as described by Khosravi ; 2–5 loops-full of mycobacterial colonies were harvested in 500 μL double-distilled water in sterile Eppendorf tube, boiled in a water bath at 100 °C for 10 min, then centrifuged at 13,000rpm for 5 min, the supernatant was collected in a sterile Eppendorf tube and stored at −20 °C until used as a template for PCR. Amplification of the product was done as described by Kim  using the primer:
tbc1 5’-CGT ACG GTC GGC GAG CTG ATC CAA-3.
tbcR 5-CCG ACA GTC GGC GCT TGT GGG TCA-3’.
The amplified DNA of 10 resistant isolates of MTBC was commercially sequenced (Macro GEN Company, Seoul, South Korea) to detect the change of DNA sequences. The result of MTBC-resistant isolate sequences were aligned with the rpoB gene sequence of MTB H37RV strain by using Blast (http://WWW//ncbiblast).
| Results|| |
The DST showed that 30 (56.6%) isolates were sensitive to the minimum concentration of the drugs, while 23 (45.3%) were resistant to at least one anti-tuberculous drug. The resistance varied from single 12 (52.17%), double 6 (26.08%), to multi-drug resistance 5 (21.74%) as shown in [Table 1]. RIF revealed the highest resistance pattern in combination with other drugs 13 (56.53%). Among the resistant isolates, 10 (43.47%) were sensitive to RIF.
|Table 1: Sensitivity test of the MTB isolates to first line antituberculous drugs.|
Click here to view
DNA sequence analysis of 10 isolates showed no change in 5 (50%) isolates, while the others had different types of mutations. Mutations included substitution, deletion and insertion of nucleotides within and out of RRDR.
Single change was demonstrated in resistant isolates at 512 (AGC/ATC, Ser/Ile), and 475 (GTC/GGC, Val/Gly). Deletion at 487 (ATC/_TC) was observed in a susceptible isolate, but resistant to SM and ETH. Insertion was in site 496 (CGG/CAGG). In other isolates more than one change was observed at 528 (CGC/CTC, Arg/Leu), 498 (GTG/GGG, Val/Gly), and 488 (ACA/ACC, Thr/Thr) ([Table 2]).
From the above result, only two variations were demonstrated at RRDR, and the remaining variations were outside that region. No variation was detected in four resistant isolates, among which one was RIF resistant, two were resistant to INH and the fourth was SM resistant.
| Discussion|| |
Resistance to anti-tuberculous drugs is an emerging global health problem . Spread of multidrug-resistant strains of MTB has become a major public health concern in both developed and developing countries. This study documented resistance to first-line anti-tuberculous drugs in 23 (45.3%) out of 53 tested isolates. This may be due to inadequate therapy or poor drug absorption . Drug resistance was reported in Sudan .
RIF is an effective anti-TB therapy and is the key component of the short course of multi-drug therapy. Resistance to RIF predicts resistance to INH and serves as a marker of multi-drug resistance. In this study a high number of resistant isolates to RIF was observed (56.5%), unlike the result reported by Chand et al.  who reported high resistant isolates to SM. MDR resistance was observed in 21.74% of cases raising a major concern about future management of TB patients in Sudan.
RIF resistance in MTB is associated with mutations in the rpoB gene; it has been demonstrated in a genetic study that more than 95% of resistance is due to mutations in the rpoB gene . Highly conservative rpoB genes play an essential role in the physiology of MTB. DNA sequence studies indicate that more than 96% of the RIF-resistant MTB had mutations within the 81-bp hot spot region of the rpoB gene (RRDR) corresponding to codons 507–533 . In this study DNA mutations were observed within and outside the RRDR region of the rpoB gene in 5 isolates identified as resistant to anti-tuberculous drugs. Within the RRDR region, DNA mutations were detected at 512 (AGC/ATC, Ser/Ile) and 528 (CGC/CTC, Arg/Leu). The mutations outside the RRDR of the rpoB of this region were detected at different sites, including 498 (GTG/GGG, Val/Gly) 488 (ACA/ACC, Thr/Thr), which is a silent mutation. Ramasoota ) reported the same result from the study conducted in Thailand, and also reported a silent mutation at the 488 codon. Deletions and insertions, which were observed in two clinical isolates, resulted in a frame shift and a formation of a truncated and non-functional protein . No mutations were observed in 5 isolates, among which only 1 was RIF resistant and the others were resistant to other anti-tuberculous drugs; these findings were in agreement with the results reported in the study conducted in the Russian Federation , in Turkey , and in China  and in Japan .
The mutation at 528 was reported in the study conducted in Pakistan and at 512 where a double mutation was reported .
| Conclusion and recommendation|| |
This study revealed that high resistance to RIF was associated with various point mutations inside and outside of the RRDR of the rpoB gene. Molecular methods are needed for early detection of TB disease and drug resistance. The study of adequate sample size from different sites in Sudan is needed to reflect the clear picture of drug resistance in Sudan.
| Conflict of interest|| |
| Acknowledgements|| |
This study was funded by the Ministry of Higher Education and Scientific Research, Sudan. We thank all the staff members of the Chest Department, Kassala Teaching Hospital for their cooperation and the TB patients who agreed to enroll in this study. Also, our thanks to Mr. Khider Mahgoub who aided in sample collection.
| References|| |
World Health Organization (WHO), Global Tuberculosis Report, 2014.
L.P. Ormerod, Multidrug-resistant tuberculosis (MDR-TB):epidemiology, prevention and treatment, Br. Med. Bull. 73–74 (2005) 17–24.
WHO: MDR-TB and XDR-TB, Detection and Treatment, Global Tuberculosis Report, 2013.
X. Chen, B.Wang,W. Yang, F. Kong, C. Li, Z. Sun, et al, Rolling circle amplification for direct detection of rpoB gene mutations in Mycobacterium tuberculosis
isolates from clinical specimens, J. Clin. Microbiol. 52 (5) (2014 May) 1540–1548, http://dx.doi.org/10.1128/JCM.00065-14
(Epub 2014 Feb 26).
S. Ramaswamy, J.M. Musser, Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis
: 1998 update, Tuberc. Lung Dis. 79 (1998) 3–29.
P. Dobner, S. Rusch-Gerdes, G. Bretzel, K. Feldmann, M. Rifai, T. Loscher, et al, Usefulness of Mycobacterium tuberculosis
genomic mutations in the genes katG and inhA for the prediction of Isoniazid resistance, Int. J. Tuberc. Lung Dis. 1 (1997) 365–369.
WHO, Global Tuberculosis Control Surveillance, Planning, Financing, Geneva, Switzerland, 2007, WHO/HTM/TB/ 2007.376.
G.S. Sharaf Eldin, I. Fadl-Elmula, M.S. Ali, A.B. Ali, A.L.G.A. Salih, K. Mallard, et al, Tuberculosis in Sudan: a study of Mycobacterium tuberculosis
strain genotype and susceptibility to anti-tuberculosis drugs, BMC Infect. Dis. 11 (2011) 219, http://dx.doi.org/10.1186/1471-2334-11-219
S. Sethi, S. Sharma, S.K. Sharma, S.K. Meharwal, S.K. Jindal, M. Sharma, Drug susceptibility of Mycobacterium tuberculosis
to primary antitubercular drugs by nitrate reductase assay, Indian J. Med. Res. 120 (2004) 468–471.
A.D. Khosravi, A. Dezfulian, S.M. Alavi, Detection of Isoniazid and Rifampin resistant Mycobacterium tuberculosis
isolated from tuberculosis patients using conventional method and PCR, Pak. J. Med. Sci. 22 (1) (2006) 47–50.
B.J. Kim, S.K. Hong, K.H. Lee, Y.J. Yun, E.C. Kim, Y.G. Park, et al, Differential identification of Mycobacterium tuberculosis
complex and nontuberculous mycobacteria by duplex PCR assay using the RNA polymerase gene (rpoB), J. Clin. Microbiol. 42 (2004) 1308–1312.
A. Pablos-Medez, M.C. Raviglione, A. Laszloo, N. Binkin, et al, Global surveillance for antituberculosis-drug resistance, The new England Journal of Medicine 338 (4) (1998) 1641–1649.
R.F. Jacobs, Multiple-drug-resistant tuberculosis, Clin. Infect. Dis. 19 (1994) 1–8.
S.O. Hassan, M.T. Musa, H.M. Elsheikh, A.M.S. Eleragi, N.S. Saeed, Drug resistance in Mycobacterium tuberculosis
isolates from northeastern Sudan, Br. J. Med. Med. Res. 2 (3) (2012) 424–433.
Col.K. Chand, Lt.Col.R. Khandelwal, Lt.Col.V. Vardhan, Resistance to antituberculosis drugs in pulmonary tuberculosis, MJAFI 62 (2006) 325–327.
J.R. Glynn, J. Whiteley, P.J. Bifani, K. Kremer, D. Van Soolingen, Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis
: a systematic review, Emerg. Infect. Dis. 8 (2002) 843–849.
J. Sekiguchi, T. Miyoshi-Akiyama, E. Augstynowicz-Kopec, Z. Zwolska, et al, Detection of multidrug resistance in Mycobacterium tuberculosis
, J. Clin. Microbiol. 45 (2007) 179– 192.
P. Ramasoota, P. Pitaksajjakul, W. Phatihattakorn, V. Pransujarit, J. Boonyasopun, Mutation in the rpoB gene of rifampicin-resistant Mycobacterium tuberculosis
strains from Thailand and its evolutionary implication, Southeast Asian J. Trop. Med. Public Health 37 (2006) 136–147.
S.Z. Bostanabad, E.A. Graviss, A.R. Bahrmand, L.P. Titov, S.A. Nojoumi, Multiple mutations in the rpoB gene of Mycobacterium tuberculosis
isolates correlate with high level of resistance to rifampicin in patients with active pulmonary tuberculosis in Afghanistan border of Iran, Afr. J. Microbiol. Res. 2 (2008) 95–102.
M.V. Afanas'ev, L.N. Ikryannikova, E.N. Il'ina, S.V. Sidorenko, A.V. Kuz'min, E.E. Larionova, et al, Molecular characteristics of rifampicin- and Isoniazid-resistant Mycobacterium tuberculosis
isolates from the Russian Federation, J. Antimicrob. Chemother. (2006) 1–8.
C.Z. Karahan, F. Ataly, M. Uzun, Z. Erturan, M. Atasever, N. Akar, Sequence analysis of rpoB mutation in rifampicin resistant clinical Mycobacterium tuberculosis
isolates from Turkey, J. Microb. Drug Resist. 4 (2004) 325.
J. Yue, W. Shi, J. Xie, Y. Li, E. Zeng, H. Wang, Mutation in the rpoB gene of multidrug resistant Mycobacterium tuberculosis
isolates from China, J. Clin. Microbiol. 41 (2003) 2209–2212.
O. Qazi, H. Rahman, Z. Tahir, M. Qasim, S. Khan, A.A. Anjum, et al, Mutation pattern in rifampicin resistance determining region of rpoB gene in multidrug-resistant Mycobacterium tuberculosis
isolates from Pakistan, Int. J. Mycobacteriol. 3 (3) (2014) 173–177, http://dx.doi.org/10.1016/j.ijmyco.2014.06.004
[Table 1], [Table 2]
|This article has been cited by|
||Prevalence of Drug-Resistant Tuberculosis in Sudan: A Systematic Review and Meta-Analysis
| ||Khalid Hajissa,Mahfuza Marzan,Mubarak Ibrahim Idriss,Md Asiful Islam |
| ||Antibiotics. 2021; 10(8): 932 |
|[Pubmed] | [DOI]|
||Mycobacterium tuberculosis Complex Lineage 3 as Causative Agent of Pulmonary Tuberculosis, Eastern Sudan1
| ||Yassir A. Shuaib,Eltahir A.G. Khalil,Lothar H. Wieler,Ulrich E. Schaible,Mohammed A. Bakheit,Saad E. Mohamed-Noor,Mohamed A. Abdalla,Glennah Kerubo,Sönke Andres,Doris Hillemann,Elvira Richter,Katharina Kranzer,Stefan Niemann,Matthias Merker |
| ||Emerging Infectious Diseases. 2020; 26(3): 427 |
|[Pubmed] | [DOI]|
||Sequencing of the entire rpob gene characterization of mutations in isolates of Mycobacterium tuberculosis circulating in an endemic tuberculosis setting
| ||Jorge Fernando Luna,Hilda Montero Ladrón de Guevara,Clara Luz Sampieri,Raquel Muńiz-Salazar,Roberto Zenteno-Cuevas |
| ||Journal of Global Antimicrobial Resistance. 2019; |
|[Pubmed] | [DOI]|
||Assessment of the risk factors associated with multidrug resistance tuberculosis in Sudan: a case control study
| ||Adel Hussein Elduma,Mohammad Ali Mansournia,Abbas Rahimi Foroushani,Hamdan Mustafa Hamdan Ali,Asrar M. A Salam Elegail,Asma Asma Elsony,Kourosh Holakouie-Naieni |
| ||Epidemiology and Health. 2019; : e2019014 |
|[Pubmed] | [DOI]|
||Molecular Epidemiology, Diagnostics and Mechanisms of Antibiotic Resistance in Mycobacterium tuberculosis complex in Africa: A Systematic Review of Current Reports
| ||John Osei Sekyere,Melese Abate Reta,Nontuthuko Excellent Maningi,Petrus Bernard Fourie |
| ||Journal of Infection. 2019; |
|[Pubmed] | [DOI]|